Clinical Trial Update: BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab [Phase 1]

View source ↗

Summary

An open-label Phase 1 dose-escalation trial of BDB001 in combination with atezolizumab for solid tumors, which has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Atezolizumab (atezolizumab)
• BDB001

Snippet

Sponsor: Eikon Therapeutics | Conditions: Tumor, Solid | Phase 1 | Status: COMPLETED